Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Omission of Surgery for Triple-negative Breast Cancer in Complete Response Confirmed by MRI and Macrobiopsy After Neoadjuvant Chemo-immunotherapy: a Randomized, Multicenter Phase II Trial.

NCT07357948 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT07357948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07357948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Omission of Surgery for Triple-negative Breast Cancer in Complete Response Confirmed by MRI and Macrobiopsy After Neoadjuvant Chemo-immunotherapy: a Randomized, Multicenter Phase II Trial.
Lead sponsor
Institut Curie
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
July 31, 2033
Enrollment
150 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-metastatic, triple negative breast cancer